Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies that aim to improve the delivery and effectiveness of existing chemotherapeutic agents while reducing systemic toxicity. The company operates within the biotechnology and pharmaceutical development industry, with a specific emphasis on hard-to-treat solid tumors, particularly pancreatic cancer. RenovoRx does not generate material commercial revenue and is primarily funded through public equity, grants, and financing activities, as disclosed in its SEC filings.
The company’s core value proposition is its proprietary RenovoTAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, which enables localized delivery of chemotherapy directly to tumors. RenovoRx’s lead product candidate, RPX-700, combines intra-arterial delivery of gemcitabine using its proprietary catheter system. The company was founded in 2009 and has since evolved from early-stage device development into a late-stage clinical oncology company, advancing its lead asset into Phase III clinical trials for locally advanced pancreatic cancer.
Business Operations
RenovoRx operates as a single-reportable segment, focused on oncology drug-device combination development. Its primary business activities include clinical research and development, regulatory engagement, intellectual property management, and preparation for potential commercialization. The company’s revenue model is currently non-commercial, with expenditures primarily related to clinical trials, manufacturing of investigational product, and general corporate operations.
The company controls the RenovoCath® delivery system, an FDA-cleared drug-delivery catheter designed for precise intra-arterial infusion, and the RenovoTAMP™ therapy protocol. RenovoRx conducts its clinical operations primarily through third-party clinical research organizations and manufacturing partners. Public disclosures do not indicate any material operating subsidiaries or joint ventures; data inconclusive based on available public sources regarding long-term commercial partnerships.
Strategic Position & Investments
RenovoRx’s strategic focus is centered on advancing RPX-700 through its ongoing TIGeR-PaC Phase III clinical trial, which targets patients with locally advanced pancreatic cancer who are not eligible for surgical resection. The company’s strategy emphasizes repurposing established chemotherapy agents with novel delivery methods to reduce development risk and regulatory complexity compared to entirely new molecular entities.
The company has not disclosed any major acquisitions or diversified investment portfolios. Strategic investments are primarily internal, directed toward clinical development, regulatory milestones, and intellectual property expansion around its delivery platform. RenovoRx has indicated interest in expanding the RenovoTAMP™ platform to other solid tumor indications, though additional pipeline assets beyond RPX-700 remain in early or exploratory stages based on publicly available information.
Geographic Footprint
RenovoRx is headquartered in Los Altos, California, and its operations are primarily based in the United States. Clinical trial activities are conducted across multiple U.S. medical centers, reflecting a national footprint in oncology research rather than a broad commercial presence.
The company does not report material international operations, manufacturing facilities, or overseas subsidiaries. Its global exposure is currently limited to regulatory awareness and potential future market considerations; data inconclusive based on available public sources regarding active international commercialization or investment activities.
Leadership & Governance
RenovoRx is led by an executive team with backgrounds in oncology, medical devices, and biopharmaceutical development. The company emphasizes a clinically driven strategy focused on improving patient outcomes through precision delivery technologies and disciplined capital allocation, as reflected in management commentary and public filings.
Key executives include:
- Shaun Bagai, MD – Chief Executive Officer
- Gregory J. Hoskins – Chairman of the Board
- Mark Ahn – Chief Financial Officer (title and tenure verified in public disclosures; scope of responsibilities consistent with small-cap biotechnology governance)
Information regarding additional executive officers or changes in leadership roles is limited in public summaries; data inconclusive based on available public sources for a comprehensive listing beyond those named above.